KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Share-based Compensation (2016 - 2025)

Boston Scientific (BSX) has disclosed Share-based Compensation for 17 consecutive years, with $71.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 2.9% to $71.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $299.0 million through Dec 2025, up 12.41% year-over-year, with the annual reading at $299.0 million for FY2025, 12.41% up from the prior year.
  • Share-based Compensation hit $71.0 million in Q4 2025 for Boston Scientific, down from $79.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $79.0 million in Q3 2025 to a low of $47.0 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $60.6 million across 5 years, with a median of $59.0 million in 2023.
  • Biggest five-year swings in Share-based Compensation: increased 27.5% in 2021 and later rose 1.72% in 2023.
  • Year by year, Share-based Compensation stood at $49.0 million in 2021, then grew by 12.24% to $55.0 million in 2022, then increased by 7.27% to $59.0 million in 2023, then rose by 16.95% to $69.0 million in 2024, then grew by 2.9% to $71.0 million in 2025.
  • Business Quant data shows Share-based Compensation for BSX at $71.0 million in Q4 2025, $79.0 million in Q3 2025, and $75.0 million in Q2 2025.